SCHEMBL2857010

SCHEMBL2857010

O=C(O)c1cnn(Cc2nc(-c3cccc(OCCc4ccccc4)c3)cs2)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 3/20 0.48
NR1H4 Q96RI1 1/20 0.46
EGLN1 Q9GZT9 2/20 0.43
F9 P00740 1/20 0.40
PTPN1 P18031 2/20 0.39
PTPN2 P17706 1/20 0.39
ACP1 P24666 1/20 0.39
KLKB1 P03952 3/20 0.39
ALDH1A1 P00352 1/20 0.39
MRGPRX4 Q96LA9 2/20 0.39
CSNK2A1 P68400 1/20 0.38
CPT2 P23786 1/20 0.38
CPT1A P50416 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2859048 0.91 HDAC3 (0.40) ALKBH1NR1H4EGLN1KLKB1ALDH1A1
SCHEMBL1198990 0.91 EGLN1 (0.52) ALKBH1NR1H4EGLN1MRGPRX4PPARD
SCHEMBL2862881 0.89 KMT2A (0.46) NR1H4EGLN1ALDH1A1CSNK2A1PPARD
SCHEMBL1197885 0.88 CSNK2A1 (0.43) EGLN1KLKB1ALDH1A1CSNK2A1PPARD
SCHEMBL1198645 0.88 KDM4E (0.43) NR1H4KLKB1ALDH1A1KDM4ENPC1
SCHEMBL2879638 0.88 HDAC3 (0.46) ALKBH1EGLN1KLKB1ALDH1A1CSNK2A1
SCHEMBL12875775 0.87 RXRA (0.50) EGLN1ALDH1A1CSNK2A1PPARDPPARA
SCHEMBL1198543 0.87 GAA (0.44) ALKBH1EGLN1KLKB1ALDH1A1CSNK2A1
SCHEMBL2861490 0.87 ALKBH1 (0.44) ALKBH1EGLN1ALDH1A1MRGPRX4PPARD
SCHEMBL2858483 0.86 NR4A2 (0.49) ALKBH1EGLN1F9KLKB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed
WO-2009123316-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF 武田薬品工業株式会社 (JP) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALKBH1 1916/4885NR1H4 3480/4885EGLN1 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.